TN8 Stock Chart & Stats
€496.50
€9.10(1.83%)
At close: 4:00 PM EDT
€496.50
€9.10(1.83%)
Day’s Range― - ―
52-Week Range€375.00 - €548.90
Previous CloseN/A
Volume472.00
Average Volume (3M)1.25K
Market Cap
€194.10B
Enterprise Value€228.94K
Total Cash (Recent Filing)€4.06B
Total Debt (Recent Filing)€42.55B
Price to Earnings (P/E)32.4
Beta0.56
Next Earnings
Oct 28, 2026EPS Estimate
5.55Next Dividend Ex-DateN/A
Dividend Yield0.3%
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume3,426
30 Day Avg. Volume1,250
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€535.45Price Target Upside7.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)21.76
Revenue Forecast (FY)€41.49B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow And ConversionThermo Fisher's robust cash generation (TTM operating cash flow ~$9.0B and FCF ~$7.3B, converting ~81% of net income) provides durable funding for R&D, capex, buybacks and M&A. This high-quality FCF underpins strategic flexibility and resilience across business cycles over the next months.
Recurring Consumables And Installed BaseThe business model centers on consumables, reagents and services tied to an extensive installed instrument base, creating predictable, repeatable revenue and high customer stickiness. That structural recurring revenue supports steady cash flow and reduces volatility in near-to-medium term performance.
Acquisitions And Product Innovation Fueling GrowthRecently closed acquisitions are integrating well and are expected to add material revenue/EPS (~$1.6B revenue, ~$0.32 EPS for 2026) while multiple product launches and AI-enabled platforms are supporting share gains. This combination strengthens mid-term growth and can help restore favorable mix and margins.
Bears Say
Elevated Leverage And Interest CostsHigher absolute debt (~$42.5B) and leverage (~3.6x gross debt/EBITDA) increase sensitivity to higher interest rates and reduce financial flexibility. Ongoing net interest (~$660M projected) constrains FCF allocation to growth investments or buybacks and raises refinancing risk if macro conditions deteriorate.
Margin Compression Vs. Prior YearsMargins remain meaningfully below 2021–2022 peaks (gross and net margin declines), reflecting mix shifts and cost pressures. If unfavorable product mix or strategic investments persist, restoring historical profitability will require sustained productivity gains or pricing power, limiting near-term return expansion.
Shareholder Dissent On Executive PayRejection of the say-on-pay advisory signals investor dissatisfaction with compensation practices. This governance friction can prompt board engagement, compensation redesign or activist involvement, creating potential distraction and complicating retention incentives critical for long-term strategy execution.
Thermo Fisher News
TN8 FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was €375.00 and its highest was €548.90 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is €194.10B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Oct 28, 2026 which is in 76 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jul 23, 2026. The company reported €5.229 earnings per share for the quarter, beating the consensus estimate of €4.959 by €0.27.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher pays a Quarterly dividend of €0.407 which represents an annual dividend yield of 0.3%. See more information on Thermo Fisher dividends here
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 5.55.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of €5.229 in its last earnings report, beating expectations of €4.959. Following the earnings report the stock price went up 11.243%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in DE:TN8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€535.45 (7.85% Upside)
€535.45 (7.85% Upside)
Blogger Sentiment
Bullish
DE:TN8 Sentiment 64%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €3.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.40%
12-Months-Change
Fundamentals
Return on Equity
0.30%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TN8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all DE:TN8 earnings summariesTN8 Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TN8 Stock 12 Month Forecast
Average Price Target
€535.45
▲(7.85% Upside)